Promising Clinical Trial Data and Upcoming Presentations Bolster Buy Rating for Mersana Therapeutics

William Blair analyst Andy Hsieh has maintained their bullish stance on MRSN stock, giving a Buy rating on May 19.

Andy Hsieh has given his Buy rating due to a combination of factors including the promising data from Mersana Therapeutics’ ongoing clinical trials. The abstracts released for the 2025 ASCO annual meeting highlighted the potential of their product, Emi-Le, in treating multiple solid tumors, which was supported by Phase I data that aligns with earlier disclosures from the company.
Furthermore, the upcoming conference presentation is expected to provide updated results, which could further validate the efficacy of their treatment. The ongoing Phase I expansion study in triple-negative breast cancer, particularly in patients with prior exposure to topoisomerase-I antibody-drug conjugates, adds another layer of potential success for Mersana. These factors collectively contribute to the positive outlook and the Buy rating assigned by Andy Hsieh.

In another report released on May 19, Leerink Partners also maintained a Buy rating on the stock with a $2.00 price target.